ReviewJournal of translational medicine2009
Recent progress towards development of effective systemic chemotherapy for the treatment of malignant brain tumors.
Review in Journal of translational medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 83 citations in OpenAlex.
- A Systematic Review of Nanoparticle-Mediated Ferroptosis in Glioma Therapy.International journal of nanomedicine · 2025Pooled it
- Molecular targeting of glioblastoma: Drug discovery and therapies.Trends in molecular medicine · 2011Trial
- The curse of blood-brain barrier and blood-tumor barrier in malignant brain tumor treatment.International journal of clinical oncology · 2025Review
- Assessing Discharge Readiness and Factors in Peripherally Inserted Central Catheter Carriers with Malignant Tumors: A Meta-Analysis.Iranian journal of public health · 2025Review
- Drug Permeability: From the Blood-Brain Barrier to the Peripheral Nerve Barriers.Advanced therapeutics · 2023Article
- Current Strategies to Enhance Delivery of Drugs across the Blood-Brain Barrier.Pharmaceutics · 2022Review
- Nanotechnology-based drug delivery for the treatment of CNS disorders.Translational neuroscience · 2022Review
- Surface Engineered Dendrimers: A Potential Nanocarrier for the Effective Management of Glioblastoma Multiforme.Current drug metabolism · 2022Review
- Modulation of Blood-Brain Barrier Permeability by Activating Adenosine A2 Receptors in Oncological Treatment.Biomolecules · 2021Review
- Dendrimer-Based Nanomedicine (Paramagnetic Nanoparticle, Nanocombretastatin, Nanocurcumin) for Glioblastoma Multiforme Imaging and Therapy.Novel approaches in cancer study · 2021Article
- Intranasal Delivery of Nanoformulations: A Potential Way of Treatment for Neurological Disorders.Molecules (Basel, Switzerland) · 2020Review
- Multifunctional Polymeric Nanoplatforms for Brain Diseases Diagnosis, Therapy and Theranostics.Biomedicines · 2020Review
- Chitosan Engineered PAMAM Dendrimers as Nanoconstructs for the Enhanced Anti-Cancer Potential and Improved In vivo Brain Pharmacokinetics of Temozolomide.Pharmaceutical research · 2018Article
- MRI Monitoring of Cerebral Blood Flow after the Delivery of Nanocombretastatin across the Blood Brain Tumor Barrier.Journal of nanomedicine & nanotechnology · 2018Article
- Nanotheranostics: Emerging Strategies for Early Diagnosis and Therapy of Brain Cancer.Nanotheranostics · 2018Review
- Intranasal administration of carbamazepine-loaded carboxymethyl chitosan nanoparticles for drug delivery to the brain.Asian journal of pharmaceutical sciences · 2018Article
- Current Strategies for Brain Drug Delivery.Theranostics · 2018Review
- Application of Dendrimer-based Nanoparticles in Glioma Imaging.Journal of nanomedicine & nanotechnology · 2017Article
- Targeting Glioma with a Dual Mode Optical and Paramagnetic Nanoprobe across the Blood-brain Tumor Barrier.Journal of nanomedicine & nanotechnology · 2016Article
- Conserved molecular mechanisms underlying the effects of small molecule xenobiotic chemotherapeutics on cells.Molecular and clinical oncology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Systemic chemotherapy has been relatively ineffective in the treatment of malignant brain tumors even though systemic chemotherapy drugs are small molecules that can readily extravasate across the porous blood-brain tumor barrier of malignant brain tumor microvasculature. Small molecule systemic chemotherapy drugs maintain peak blood concentrations for only minutes, and therefore, do not accumulate to therapeutic concentrations within individual brain tumor cells. The physiologic upper limit of pore size in the blood-brain tumor barrier of malignant brain tumor microvasculature is approximately 12 nanometers. Spherical nanoparticles ranging between 7 nm and 10 nm in diameter maintain peak blood concentrations for several hours and are sufficiently smaller than the 12 nm physiologic upper limit of pore size in the blood-brain tumor barrier to accumulate to therapeutic concentrations within individual brain tumor cells. Therefore, nanoparticles bearing chemotherapy that are within the 7 to 10 nm size range can be used to deliver therapeutic concentrations of small molecule chemotherapy drugs across the blood-brain tumor barrier into individual brain tumor cells. The initial therapeutic efficacy of the Gd-G5-doxorubicin dendrimer, an imageable nanoparticle bearing chemotherapy within the 7 to 10 nm size range, has been demonstrated in the orthotopic RG-2 rodent malignant glioma model. Herein I discuss this novel strategy to improve the effectiveness of systemic chemotherapy for the treatment of malignant brain tumors and the therapeutic implications thereof.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.